Loading
Michelle Brown

Michelle Brown

Vice President, Portfolio Lead, Moderna
Michelle Brown, MD PhD, obtained her dual degree and post-doctoral training from the University of Utah and Huntsman Cancer Institute with focus on understanding the mechanisms of oncogenesis in pediatric oncology. As a Portfolio Lead at Moderna, Michelle is responsible for driving overarching development strategy/priorities across the individualized neoantigen therapy (INT) portfolio and ensuring harmonized design and execution of Moderna’s current and emerging mRNA-based oncology cancer therapeutics programs. Michelle empowers the INT Program Leaders and cross-functional teams to work towards delivering on the promise of mRNA science to create a new generation of transformative medicines for oncology patients. Prior to joining Modera, Michelle was a clinical development lead at Bristol-Myers Squibb, and was responsible for multiple novel immuno-oncology programs spanning from first in human to registration and helped launch the anti-PD1 and anti-CTLA4 checkpoint inhibitors into clinical practice. Early in her career, she worked in medical affairs specializing in immuno-oncology, biomarkers, and solid tumors. Her work has resulted in numerous peer-reviewed publications and supports the advancement of oncology treatment paradigms.
Sessions

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS